Skip to content
MedsAcross

Medicine

Idarubicin 20 mg/20 mL injection

Idarubicin · Intravenous
Available on requestPrescription onlyUS FDA Cold chainGeneric name

Idarubicin 20 mg/20 mL injection is a generic prescription medicine for intravenous use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

Store under refrigeration 2° to 8°C (36° to 46°F), and protect from light.

Key facts

Active ingredient (INN)
Idarubicin
Brand
Sold under the generic name
Strength
20 mg/20 mL
Dosage form
Injection
Route
Intravenous
Packs
1 vial of 20 mL
Manufacturers
Hikma PharmaceuticalsMeitheal Pharmaceuticals
Origin register
US FDA, United States
Storage
Store under refrigeration 2° to 8°C (36° to 46°F), and protect from light.
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01DB06 Idarubicin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 January 2017
Identifiers
RxCUI 1791493, 1791498, 1791500DailyMed set ID b9b337d5-50f7-4ea9-9df4-72c86e4c0b91, 7c20b574-285b-49eb-a98e-6752e4bb481d, d31254be-6bd2-4ac1-acab-bc00e2209d28NDC 0143-9219, 0143-9308, 71288-186Application ANDA065275, ANDA065036

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial, glass in 1 box / 20 mL in 1 vial, glass0143-9219-01Hikma Pharmaceuticals30 January 2017
1 vial, glass in 1 box / 20 mL in 1 vial, glass0143-9308-01Hikma Pharmaceuticals12 January 2018
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose71288-186-20Meitheal Pharmaceuticals1 June 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 27 September 1990Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Idarubicin 20 mg/20 mL injection.

Compare 1

Other strengths and forms of Idarubicin

Clinical summary

Idarubicin is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. It is available as injection for intravenous use. MedsAcross supplies Idarubicin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Idarubicin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Idarubicin 20 mg/20 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.